Core Insights - Viking Therapeutics has completed patient enrollment ahead of schedule for its Phase 3 VANQUISH-1 clinical trial of VK2735, indicating strong interest in new obesity treatments [1][3] - The trial enrolled approximately 4,650 adults with obesity or overweight conditions, assessing the efficacy and safety of VK2735 over 78 weeks [2] - Positive results from the Phase 2 VENTURE study of VK2735 showed significant weight reduction and favorable safety profiles [4] Company Overview - Viking Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel therapies for metabolic and endocrine disorders, with VK2735 being a dual agonist of GLP-1 and GIP receptors [1][6] - The company is also developing VK2809 for lipid and metabolic disorders and VK0214 for X-linked adrenoleukodystrophy [7] Clinical Trials - The Phase 3 VANQUISH-1 study is a randomized, double-blind, placebo-controlled trial with four treatment arms, focusing on weight change from baseline as the primary endpoint [2] - A 52-week extension period is included for participants to continue treatment after the primary dosing period [2] - Concurrently, the Phase 3 VANQUISH-2 study is enrolling patients with type 2 diabetes and obesity, expected to complete enrollment in Q1 2026 [3] Mechanism of Action - VK2735 acts on GLP-1 and GIP receptors, which are known to decrease glucose levels, reduce appetite, and improve insulin sensitivity [5] - The dual agonist approach aims to enhance therapeutic benefits compared to existing treatments [5]